医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Open Monoclonal Technology Announces OmniAb™ Alliance with Celgene

2015年03月11日 AM02:06
このエントリーをはてなブックマークに追加


 

PALO ALTO, Calif.

Open Monoclonal Technology, Inc. (OMT) today announced a license that provides Celgene Corporation (Celgene) with unlimited access to OMT’s proprietary OmniRat®, OmniMouse® and OmniFlic™ platforms for generation of human antibody therapeutics.

Dr. Roland Buelow, founder and CEO of OMT, commented, “Celgene is a global leader in novel therapies for cancer and inflammatory diseases where human therapeutic antibodies are particularly useful. The company will become OMT’s 11th partner with unlimited platform access. OMT will facilitate rapid and efficient technology integration into Celgene and believes it will be enabling for the company’s growing pipeline of antibody therapeutics.”

About Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for generation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with four transgenic animal platforms, jointly OmniAb.

OmniRat® is the industry’s first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. UniRat is the first transgenic rat generating fully human heavy chain-only antibodies and nanobodies for polyspecific applications.

All four OmniAb™ platforms deliver human antibodies with high affinity, specificity, expression, solubility and stability. They use patented technology, have broad freedom to operate and are available worldwide for all targets and indications. Current partners include Celgene, Chugai, Genmab, Genentech, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen, an undisclosed global pharmaceutical company and several smaller biotech companies and universities. OmniAb antibody discovery services are available via Antibody Solutions in the US, Aldevron in Germany and WuXi AppTec in China.

For more information, please visit www.omtinc.net.

CONTACT

Open Monoclonal Technology, Inc.
Brian Lundstrom, +1-775-420-7750
Chief
Business Officer
bl@omtinc.net

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402